Visium Asset Management LP, a $4.5 billion hedge fund firm, said on Thursday that it is forming a new investment platform focused on healthcare royalties. The company has hired four people from Paul Capital, a private investment firm, to run the platform. They are Dr. Ken Macleod, John Leone, David Lippman and Julie Rahman. All will join Visium on June 1, 2013. The group will be based in Visium’s New York and London offices. Also, as part of Visium, they will also serve as sub-advisors to Paul Capital’s existing healthcare and royalty funds.
NEW YORK & LONDON–(BUSINESS WIRE)–Visium Asset Management LP (“Visium”), a leading multi-strategy investment firm that oversees $4.5 billion of assets, today announced that it is forming a new investment platform focused on healthcare royalties and related revenues. The platform will be run by four seasoned executives – Dr. Ken Macleod, John Leone, David Lippman and Julie Rahman – who will join Visium from Paul Capital, a leading private investment firm, on June 1, 2013. The group will be based in Visium’s New York and London offices and, as part of Visium, also serve as sub-advisor to Paul Capital’s existing healthcare and royalty funds.
“Healthcare royalty investing is a natural fit with Visium’s growing business, and we are pleased to welcome this talented investment team to our firm,” said Jacob Gottlieb, Founder and Chief Investment Officer, of Visium. “We look forward to leveraging our robust operational infrastructure and international reach as we expand into this attractive investment area.”
Dr. Macleod, Managing Partner of Visium Healthcare Finance, who will lead the initiative, said, “We are pleased to be joining Jacob Gottlieb and Visium, whose deep healthcare investing background and global platform will provide access to new sources of deal flow and to Visium’s broader industry insights.”
Phil Jensen, a Partner of Paul Capital, said, “Visium has a stellar reputation and we are pleased to collaborate with them on the continued management of our healthcare investment business.”
While at Paul Capital, Dr. Macleod was responsible for managing the European investment team which pursued healthcare investment opportunities in the pharmaceutical and biotechnology industries. Prior to joining Paul Capital in 2004, Dr. Macleod held senior management positions over a 15-year career at Serono, Abbott Laboratories and Beecham Pharmaceuticals, and was a Venture Partner at Schroder Ventures Life Sciences. Dr. Macleod earned his Ph.D. from the University of York, UK and his B.Sc. in Biology from the University of Manchester, UK.
About Visium Asset Management:
Visium Asset Management (www.visiumfunds.com ) is a $4.5 billion multi-strategy alternative asset manager founded in 2005. The firm has more than 100 professionals, and manages investments in long/short equity, credit, event-driven and multi-strategy funds.